LINC02418: A Potential Drug Target and Biomarker (G100190940)

Target Name: LINC02418

NCBI ID: G100190940

LINC02418

Other Name(s): long intergenic non-protein coding RNA 2418 | Long intergenic non-protein coding RNA 2418

LINC02418: A Potential Drug Target and Biomarker

LINC02418 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer. LINC02418 has been shown to play a role in the regulation of cell proliferation, apoptosis, and angiogenesis, which are important processes that are critical for the development and progression of cancer.

The discovery of LINC02418 as a potential drug target and biomarker has significant implications for the development of new cancer therapies. Cancer is a leading cause of death worldwide, and there is a high demand for effective and targeted therapies that can effectively treat this disease. LINC02418 has been shown to be a promising target for cancer therapy, and further research is being conducted to determine its effectiveness.

One of the key advantages of LINC02418 as a potential drug target is its ability to be targeted with small molecules. LINC02418 is a small RNA molecule that is expressed in all cell types, making it an attractive target for small molecules that can be easily administered to patients. Small molecules have been shown to be effective in targeting a wide range of molecules, including RNA molecules, proteins, and other biomolecules.

Another advantage of LINC02418 as a potential drug target is its role in the regulation of cell cycle progression. The cell cycle is the process by which cells grow, divide, and replicate themselves. LINC02418 is involved in the regulation of the cell cycle by controlling the entry of cells into the G1 phase and the exit of cells from the G1 phase. This regulation is important for the development and progression of cancer, as alterations in the cell cycle can contribute to the development of cancer.

In addition to its role in cell cycle regulation, LINC02418 has also been shown to play a role in the regulation of apoptosis. Apoptosis is the process by which cells undergo programmed cell death, which is important for the development and progression of cancer. LINC02418 is involved in the regulation of apoptosis by controlling the expression of genes that are involved in cell death.

Furthermore, LINC02418 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. Angiogenesis is important for the development and progression of cancer, as it provides the necessary blood supply for the growth and expansion of cancer cells. LINC02418 is involved in the regulation of angiogenesis by controlling the expression of genes that are involved in blood vessel formation.

In conclusion, LINC02418 is a promising potential drug target and biomarker. Its role in cell cycle regulation, apoptosis, and angiogenesis makes it an attractive target for small molecules that can be used to develop new cancer therapies. Further research is needed to determine the effectiveness of LINC02418 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2418

The "LINC02418 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02418 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets